J. Hinkle, J. Hinson, E. Kerwin
Aug 1, 2011
Citations
0
Influential Citations
9
Citations
Quality indicators
Journal
Pediatric Pulmonology
Abstract
Short‐acting β2‐agonists (SABAs) are recommended for treating acute pediatric asthma. The long‐acting β2‐agonist (LABA) arformoterol is approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Arformoterol acts rapidly, is delivered via nebulization, and, as such, raises concerns from the FDA over possible off‐label use in acute asthma in children. As a step to investigate this issue, this study evaluated the safety and tolerability of three consecutive doses of arformoterol administered over 1 hr in children with stable asthma.